Klobuchar Wants To Stop 鈥楶ay-For-Delay鈥 Deals That Keep Drug Prices High
It鈥檚 as shady as it sounds.
Drugs
801 - 820 of 1,299 Results
-
-
Pain Clinics’ Doctors Needlessly Tested Hundreds Of Urine Samples, Court Records Show
Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
By Fred Schulte -
Amid Opioid Prescriber Crackdown, Health Officials Reach Out To Pain Patients
After dozens of health care workers were charged with illegally prescribing opioids in Appalachia, local health agencies are trying to make sure chronic pain patients don't fall through the cracks.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Mulvaney: Trump Brought Down Drug Prices For The First Time In 50 Years
It鈥檚 "within spitting distance of something that鈥檚 true," said one health economist. But our fact check found it wasn't quite there.
-
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday鈥檚 House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade鈥檚 300% price increase, frustrating congressional representatives.
By Rachel Bluth -
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee鈥檚 third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
By Rachel Bluth -
Consumers Rejected Drug Plan That Mirrors Trump Administration Proposal
What to know about PBMs and rebates ahead of the Senate drug price hearing on 鈥 you guessed it 鈥 PBMs.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Doughnut Hole Is Gone, But Medicare’s Uncapped Drug Costs Still Bite Into Budgets
Beneficiaries pay 25 percent of the price of their brand-name drugs until they reach $5,100 in out-of-pocket costs. After that, their obligation drops to 5 percent. But it never disappears.
-
Analysis: Why Americans Shouldn鈥檛 Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
-
Must-Reads Of The Week (Some Flying Below The Radar)
Executive editor Damon Darlin takes a spin as host of 鈥淭he Friday Breeze,鈥 whirling through a week of health care news so you don鈥檛 have to.
By Damon Darlin -
Podcast: KHN鈥檚 鈥榃hat The Health?鈥 The Karma Of Cutting Medicare
Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump鈥檚 budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA鈥檚 crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
-
How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don鈥檛 have to.
-
Lawmakers United Against High Drug Prices Bare Partisan Teeth
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
By Rachel Bluth -
Cities And Counties Unlikely To Heed FDA Warning On Importing Foreign Drugs
The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent 鈥渦napproved鈥 and 鈥渕isbranded鈥 drugs to U.S. consumers, jeopardizing their safety.
-
The Promise Of Youth, The Reality Of Aging
Patients Experiment With Prescription Drugs To Fight Aging
Doctors and patients say they鈥檙e compelled to use off-label meds as research goes unfunded.
-
Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes
A KHN database shows that $58 million flowed from drugmakers to patient groups running national ads.